OneMedNet Corp (ONMD) Latest Company News

Oct 19, 2026, 12:45 UTC
OneMedNet Corp signed its 12th channel partner agreement with an unnamed global pharmaceutical intelligence and data solutions provider to distribute OneMedNet’s U.S.-sourced, de-identified clinical data to pharmaceutical customers worldwide.
Source:
- globenewswire.com
Oct 15, 2026, 12:45 UTC
OneMedNet announced a partnership adding a leading hospital system to its iRWD platform and federated provider network, with expansion of up to 12 additional hospitals expected.
Source:
- globenewswire.com
Oct 7, 2026, 12:30 UTC
OneMedNet announced a channel partner agreement with C&R Research, Inc., appointing it as distributor of OneMedNet’s U.S.-sourced real-world data in Korea and extending its commercial reach into the Asia Pacific region.
Source:
- globenewswire.com
Sep 30, 2026, 12:55 UTC
OneMedNet Corporation signed a seven-figure multiyear agreement to supply de-identified, multimodal, longitudinal clinical Real World Data to a commercially scaled AI-enabled precision medicine company.
Source:
- globenewswire.com
Sep 25, 2026, 15:50 UTC
OneMedNet Corporation announced a 1-for-10 reverse stock split of its issued and outstanding common shares, effective at 12:01 a.m. on a date to be set.
Source:
- globenewswire.com
Sep 23, 2026, 21:03 UTC
OneMedNet Corp elected Dr. Kenneth Alleyne, Sherry Coonse McCraw, and Dr. Jeffrey Yu as Class III directors effective September 18, 2026.
Sep 22, 2026, 12:40 UTC
OneMedNet Corporation entered a multi-year resale agreement with Atropos Health to expand commercial reach for its AI-driven real-world data offerings.
Source:
- globenewswire.com
Sep 18, 2026, 12:35 UTC
OneMedNet Corporation announced year-to-date bookings of approximately $16.2 million, a 16-fold increase versus the same period in 2025.
Source:
- globenewswire.com
Aug 31, 2026, 12:35 UTC
OneMedNet Corporation announced a new agreement to deliver de-identified clinical Real-World Data to a leading AI-driven drug development company, with the iRWD platform enabling feasibility, validation, and contract signing within three weeks of initial contact.
Source:
- globenewswire.com
Aug 17, 2026, 13:10 UTC
OneMedNet reported its quarterly results for the period ended June 30, 2026, disclosing zero Bitcoin holdings, $358,000 in cash, $4.73 million in current liabilities, and a going-concern warning about insufficient liquidity for the next 12 months.
Source:
- cryptoslate.com
Jul 28, 2026, 12:30 UTC
OneMedNet entered into an agreement to supply regulatory-grade real-world data for foundational AI model development.
Source:
- globenewswire.com

ONMD

OneMedNet Corp signed its 12th channel partner agreement with an unnamed global pharmaceutical intelligence and data solutions provider to distribute OneMedNet’s U.S.-sourced, de-identified clinical data to pharmaceutical customers worldwide.

OneMedNet announced a partnership adding a leading hospital system to its iRWD platform and federated provider network, with expansion of up to 12 additional hospitals expected.

OneMedNet announced a channel partner agreement with C&R Research, Inc., appointing it as distributor of OneMedNet’s U.S.-sourced real-world data in Korea and extending its commercial reach into the Asia Pacific region.

OneMedNet Corporation signed a seven-figure multiyear agreement to supply de-identified, multimodal, longitudinal clinical Real World Data to a commercially scaled AI-enabled precision medicine company.

OneMedNet Corporation announced a 1-for-10 reverse stock split of its issued and outstanding common shares, effective at 12:01 a.m. on a date to be set.

OneMedNet Corp elected Dr. Kenneth Alleyne, Sherry Coonse McCraw, and Dr. Jeffrey Yu as Class III directors effective September 18, 2026.

OneMedNet Corporation entered a multi-year resale agreement with Atropos Health to expand commercial reach for its AI-driven real-world data offerings.

OneMedNet Corporation announced year-to-date bookings of approximately $16.2 million, a 16-fold increase versus the same period in 2025.

OneMedNet Corporation announced a new agreement to deliver de-identified clinical Real-World Data to a leading AI-driven drug development company, with the iRWD platform enabling feasibility, validation, and contract signing within three weeks of initial contact.

OneMedNet reported its quarterly results for the period ended June 30, 2026, disclosing zero Bitcoin holdings, $358,000 in cash, $4.73 million in current liabilities, and a going-concern warning about insufficient liquidity for the next 12 months.

OneMedNet entered into an agreement to supply regulatory-grade real-world data for foundational AI model development.